Aug 1 Biogen Inc said it would exercise
an option to develop and commercialize an experimental genetic
muscle-disorder drug after an interim analysis of late-stage
data showed patients experienced a statistically significant
improvement in symptoms.
The drug, nusinersen, was being developed by Biogen in
collaboration with Ionis Pharmaceuticals Inc, and the
U.S. drugmaker on Monday said it had paid Ionis a $75 million
The drug is being tested to treat spinal muscular atrophy
(SMA), a genetic disease affecting the part of the nervous
system that controls voluntary muscle movement.
In the interim analysis, nusinersen met the main goal in the
study in infants with a form of SMA, and was found to have an
acceptable safety profile.
Based on this data, the trial will be stopped, and all the
patients will now receive the drug in a follow-on study, the
(Reporting by Natalie Grover in Bengaluru; Editing by Shounak